tiprankstipranks
Advertisement
Advertisement

AVBP Stock Latest News

Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data
RatingsAnalyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data
2d ago
AVBP
ArriVent Biopharma assumed with a Buy at Truist
PremiumThe Fly
ArriVent Biopharma assumed with a Buy at Truist
5d ago
AVBP
ArriVent Biopharma price target lowered to $43 from $45 at Citi
PremiumThe Fly
ArriVent Biopharma price target lowered to $43 from $45 at Citi
21d ago
AVBP
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
PremiumRatings
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
22d ago
AVBP
ArriVent BioPharma Updates At-The-Market Equity Offering Program
PremiumCompany Announcements
ArriVent BioPharma Updates At-The-Market Equity Offering Program
22d ago
8K
AVBP
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
PremiumThe FlyArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
22d ago
AVBP
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
23d ago
AVBP
ArriVent Biopharma announces FDA clearance of ARR-002 NDA
Premium
The Fly
ArriVent Biopharma announces FDA clearance of ARR-002 NDA
27d ago
AVBP
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
1M ago
AVBP
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
PremiumThe Fly
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
1M ago
AVBP
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
PremiumThe Fly
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
2M ago
AVBP
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
PremiumCompany Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
3M ago
8K
AVBP
ArriVent Biopharma assumed with a Buy at BTIG
PremiumThe FlyArriVent Biopharma assumed with a Buy at BTIG
3M ago
AVBP
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
Premium
Ratings
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
3M ago
AVBP
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
Premium
The Fly
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
3M ago
AVBP
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
PremiumThe Fly
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
3M ago
AVBP
ArriVent Biopharma price target raised to $33 from $31 at Citi
PremiumThe Fly
ArriVent Biopharma price target raised to $33 from $31 at Citi
3M ago
AVBP
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
PremiumThe Fly
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
4M ago
ET
ABR
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
PremiumRatings
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
5M ago
AVBP
ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
PremiumRatingsArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
5M ago
AVBP
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
5M ago
AVBP
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study
Premium
The Fly
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study
5M ago
AVBP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >